<DOC>
	<DOCNO>NCT01432587</DOCNO>
	<brief_summary>An ongoing trial diflunisal close enrollment , thus , patient suitable study longer participate receive treatment diflunisal ; patient , participate trial continue treatment . The investigator want continue monitor effect drug transthyretin ( TTR ) amyloidosis open label observational study . Primary endpoint composite score manifestation disease ( Kumamoto scale ) secondary end point measurement neurological impairment , heart involvement nutritional status .</brief_summary>
	<brief_title>The Effect Diflunisal Familial Transthyretin Amyloidosis</brief_title>
	<detailed_description>Duration treatment study dependent result ongoing IND 68092-study , plan presented 2013 .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Amyloid Neuropathies , Familial</mesh_term>
	<mesh_term>Diflunisal</mesh_term>
	<criteria>Biopsy genetically proven systemic transthyretin amyloidosis cause TTR gene mutation . The amyloid shall prove transthyretin type , fibril composition settle . Age ≥ 18 year . Negative pregnancy test contraception sexually active woman child bear potential . Concomitant use nonstudy nonsteroidal antiinflammatory drug ( NSAIDs ) Heart failure symptom daily activity ( NYHA class ≥III ) Renal insufficiency ( creatinine clearance &lt; 30 ml calculate CockcroftGault formula ) Active nonhaemorrhoidal bleeding within last 18 month . Nontreated peptic ulcer disease . Anticoagulation therapy , low dose ASA permit . Nonsteroidal aspirin allergy/hypersensitivity Thrombocytopenia ( &lt; 100,000 platelets/mm3 ) Inability unwillingness subject give write inform consent By investigator regard unable follow study guideline schedule control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Amyloidosis</keyword>
	<keyword>Transthyretin</keyword>
	<keyword>Neuropathies</keyword>
	<keyword>Diflunisal</keyword>
	<keyword>Familial</keyword>
</DOC>